Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Innovent Biologics Collaborates with Roche to Advance DLL3 ADC Candidate IBI3009

CARsgen Therapeutics Announces Positive Phase II Results for Satricabtagene Autoleucel in Gastric Cancer

IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Home
/
update
/
details

Innovent Biologics Collaborates with Roche to Advance DLL3 ADC Candidate IBI3009

NextEdge Admin

02 Jan 2025

2 min 32 sec

biopharmaceutical,antibody-drug conjugate,small-cell lung cancer

Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company, has entered a collaboration and exclusive license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to develop IBI3009, a novel DLL3-targeted antibody-drug conjugate (ADC). IBI3009 has obtained IND approvals in Australia, China, and the U.S., with the first Phase 1 patient dosed in December 2024. This partnership aims to provide advanced treatment options for small-cell lung cancer.

IBI3009 targets DLL3, a protein minimally expressed in normal tissues but significantly overexpressed in small-cell lung cancer and other neuroendocrine tumors. Built on Innovent's proprietary topoisomerase 1 inhibitor (TOPO1i) platform, IBI3009 demonstrates strong anti-tumor activity in multiple chemo-resistant tumor models and a favorable safety profile, positioning it as a potentially best-in-class ADC.

Dr. Samuel Zhang, Chief Business Officer at Innovent, expressed enthusiasm for the partnership, highlighting Roche’s global expertise in oncology as a vital asset to advancing IBI3009. Boris L. Zaïtra, Roche’s Head of Corporate Business Development, emphasized the potential of this collaboration to meet the unmet needs of patients with solid tumors.

Under the agreement, Innovent grants Roche exclusive global rights to develop, manufacture, and commercialize IBI3009. The early-stage development will be a joint effort, with Roche taking over subsequent phases. Innovent will receive an $80 million upfront payment, up to $1 billion in milestone payments, and tiered royalties on global sales.

Founded in 2011, Innovent specializes in high-quality, affordable biopharmaceuticals addressing cancer, cardiovascular, autoimmune, and eye diseases. With 13 marketed products and a robust pipeline, Innovent remains committed to advancing global healthcare through innovation and collaboration.